Skip to main content
SpringerLink
Log in

Breast Cancer Metabolism

  • Chapter
The Heterogeneity of Cancer Metabolism

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1063))

  • 2941 Accesses

Abstract

Despite advances in screening, therapy, and surveillance that have improved survival rates, breast cancer is still the most commonly diagnosed cancer and the second leading cause of cancer mortality among women [1]. Breast cancer is a highly heterogeneous disease rooted in a genetic basis and reflected in clinical behavior. The diversity of breast cancer hormone receptor status and the expression of surface molecules has guided therapy decisions for decades; however, subtype-specific treatment often yields diverse responses due to varying tumor evolution and malignant potential. Although understanding the mechanisms behind breast cancer heterogeneity is still a challenge, available evidence suggests that studying its metabolism has the potential to give valuable insight into the causes of these variations, as well as viable targets for intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

3HP:

3-Phosphohydroxypyruvate

3PG:

3-Phosphoglycerate

αKG:

Alpha-ketoglutarate

CK:

Choline kinase

COMT:

Catechol-O-methyltransferase

D-2HG:

D-2-hydroxyglutarate

E2:

17b-Estradiol

ER:

Estrogen receptor

GLUT:

Glucose transporter

GSTP:

Glutathione S-transferase P

HER2:

Human epidermal growth factor receptor 2

PCho:

Phosphocholine

PHGDH:

Phosphoglycerate dehydrogenase

PR:

Progesterone receptor

PSAT1:

Phosphoserine aminotransferase 1

PSPH:

Phosphoserine phosphatase

PtdCho:

Phosphatidylcholine

TCA:

Tricarboxylic acid

TNBC:

Triple-negative breast cancer

References

  1. Gutierrez, T., et al. (2013). IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn(−/−) mice. European Journal of Immunology, 43(2), 382–393.

    Article  CAS  PubMed  Google Scholar 

  2. Hu, X., et al. (2009). Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Molecular Cancer Research, 7(4), 511–522.

    Article  CAS  PubMed  Google Scholar 

  3. Birnbaum, D. J., et al. (2011). Genome profiling of pancreatic adenocarcinoma. Genes, Chromosomes & Cancer, 50(6), 456–465.

    Article  CAS  Google Scholar 

  4. Son, J., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 496(7443), 101–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lyssiotis, C. A., et al. (2013). Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle, 12(13), 1987–1988.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Telang, S., et al. (2007). The oncoprotein H-RasV12 increases mitochondrial metabolism. Molecular Cancer, 6, 77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. White, E. (2013). Exploiting the bad eating habits of Ras-driven cancers. Genes & Development, 27(19), 2065–2071.

    Article  CAS  Google Scholar 

  8. Martinez-Outschoorn, U. E., et al. (2012). BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: Implications for breast cancer prevention with antioxidant therapies. Cell Cycle, 11(23), 4402–4413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Warburg, O., Wind, F., & Negelein, E. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519–530.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nature Reviews. Cancer, 4(11), 891–899.

    Article  CAS  PubMed  Google Scholar 

  12. Waki, A., et al. (1998). The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nuclear Medicine and Biology, 25(7), 593–597.

    Article  CAS  PubMed  Google Scholar 

  13. Choi, J., Jung, W. H., & Koo, J. S. (2013). Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology, 80(1), 41–52.

    Article  CAS  PubMed  Google Scholar 

  14. Grover-McKay, M., et al. (1998). Role for glucose transporter 1 protein in human breast cancer. Pathology Oncology Research, 4(2), 115–120.

    Article  CAS  PubMed  Google Scholar 

  15. Lloyd, S. M., Arnold, J., & Sreekumar, A. (2015). Metabolomic profiling of hormone-dependent cancers: A bird’s eye view. Trends in Endocrinology and Metabolism, 26(9), 477–485.

    Article  CAS  PubMed  Google Scholar 

  16. Katz-Brull, R., et al. (2002). Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Research, 62(7), 1966–1970.

    PubMed  CAS  Google Scholar 

  17. Eliyahu, G., Kreizman, T., & Degani, H. (2007). Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies. International Journal of Cancer, 120(8), 1721–1730.

    Article  CAS  PubMed  Google Scholar 

  18. Aboagye, E. O., & Bhujwalla, Z. M. (1999). Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Research, 59(1), 80–84.

    CAS  PubMed  Google Scholar 

  19. Hilvo, M., et al. (2011). Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Research, 71(9), 3236–3245.

    Article  CAS  PubMed  Google Scholar 

  20. Ramirez de Molina, A., et al. (2002). Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene, 21(27), 4317–4322.

    Article  CAS  PubMed  Google Scholar 

  21. Rodriguez-Gonzalez, A., et al. (2004). Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene, 23(50), 8247–8259.

    Article  CAS  PubMed  Google Scholar 

  22. Glunde, K., Bhujwalla, Z. M., & Ronen, S. M. (2011). Choline metabolism in malignant transformation. Nature Reviews. Cancer, 11(12), 835–848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fuhrman, B. J., et al. (2012). Estrogen metabolism and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute, 104(4), 326–339.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cicatiello, L., et al. (2010). Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. The American Journal of Pathology, 176(5), 2113–2130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Acconcia, F., & Kumar, R. (2006). Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Letters, 238(1), 1–14.

    Article  CAS  PubMed  Google Scholar 

  26. Jia, M., et al. (2016). Estrogen receptor alpha promotes breast cancer by reprogramming choline metabolism. Cancer Research, 76(19), 5634–5646.

    Article  CAS  PubMed  Google Scholar 

  27. Devanesan, P., et al. (2001). Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: Potential biomarkers for estrogen-initiated cancer. Carcinogenesis, 22(3), 489–497.

    Article  CAS  PubMed  Google Scholar 

  28. Cavalieri, E., et al. (2000). Estrogens as endogenous genotoxic agents--DNA adducts and mutations. Journal of the National Cancer Institute. Monographs, 27, 75–93.

    Article  CAS  Google Scholar 

  29. Bradlow, H. L., et al. (1996). 2-hydroxyestrone: The ‘good’ estrogen. The Journal of Endocrinology, 150(Suppl), S259–S265.

    PubMed  CAS  Google Scholar 

  30. Possemato, R., et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 476(7360), 346–350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Fan, J., et al. (2015). Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chemical Biology, 10(2), 510–516.

    Article  CAS  PubMed  Google Scholar 

  32. Rakheja, D., et al. (2013). The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. Frontiers in Oncology, 3, 169.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Terunuma, A., et al. (2014). MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. The Journal of Clinical Investigation, 124(1), 398–412.

    Article  CAS  PubMed  Google Scholar 

  34. Yue, W., et al. (2003). Genotoxic metabolites of estradiol in breast: Potential mechanism of estradiol induced carcinogenesis. The Journal of Steroid Biochemistry and Molecular Biology, 86(3-5), 477–486.

    Article  CAS  PubMed  Google Scholar 

  35. Mullarky, E., et al. (2016). Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proceedings of the National Academy of Sciences of the United States of America, 113(7), 1778–1783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jerby, L., et al. (2012). Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Research, 72(22), 5712–5720.

    Article  CAS  PubMed  Google Scholar 

  37. Shen, L., et al. (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 112(17), 5425–5430.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Jove, M., et al. (2017). A plasma metabolomic signature discloses human breast cancer. Oncotarget, 8(12), 19522–19533.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Huang, S., et al. (2016). Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Medicine, 8(1), 34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Giskeodegard, G. F., et al. (2010). Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. Journal of Proteome Research, 9(2), 972–979.

    Article  CAS  PubMed  Google Scholar 

  41. Mountford, C. E., et al. (2001). Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. The British Journal of Surgery, 88(9), 1234–1240.

    Article  CAS  PubMed  Google Scholar 

  42. Asiago, V. M., et al. (2010). Early detection of recurrent breast cancer using metabolite profiling. Cancer Research, 70(21), 8309–8318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Oakman, C., et al. (2011). Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Annals of Oncology, 22(6), 1295–1301.

    Article  CAS  PubMed  Google Scholar 

  44. Jobard, E., et al. (2014). A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Letters, 343(1), 33–41.

    Article  CAS  PubMed  Google Scholar 

  45. Simoes, R. V., et al. (2015). Metabolic plasticity of metastatic breast cancer cells: Adaptation to changes in the microenvironment. Neoplasia, 17(8), 671–684.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Wei, S., et al. (2013). Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Molecular Oncology, 7(3), 297–307.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Jessica Tan

  2. Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Anne Le

Authors
  1. Jessica Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne Le .

Editor information

Editors and Affiliations

  1. Johns Hopkins Medicine, Baltimore, MD, USA

    Anne Le MD, HDR

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Tan, J., Le, A. (2018). Breast Cancer Metabolism. In: Le, A. (eds) The Heterogeneity of Cancer Metabolism. Advances in Experimental Medicine and Biology, vol 1063. Springer, Cham. https://doi.org/10.1007/978-3-319-77736-8_6

Download citation

Publish with us

Policies and ethics

Search

Navigation